GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biomaxima SA (WAR:BMX) » Definitions » Capex-to-Revenue

Biomaxima (WAR:BMX) Capex-to-Revenue : 0.04 (As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Biomaxima Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Biomaxima's Capital Expenditure for the three months ended in Mar. 2024 was zł-0.47 Mil. Its Revenue for the three months ended in Mar. 2024 was zł11.53 Mil.

Hence, Biomaxima's Capex-to-Revenue for the three months ended in Mar. 2024 was 0.04.


Biomaxima Capex-to-Revenue Historical Data

The historical data trend for Biomaxima's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomaxima Capex-to-Revenue Chart

Biomaxima Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 0.03 0.06 0.07 0.39

Biomaxima Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.22 0.63 0.39 0.33 0.04

Competitive Comparison of Biomaxima's Capex-to-Revenue

For the Diagnostics & Research subindustry, Biomaxima's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomaxima's Capex-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biomaxima's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Biomaxima's Capex-to-Revenue falls into.



Biomaxima Capex-to-Revenue Calculation

Biomaxima's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-18.079) / 46.786
=0.39

Biomaxima's Capex-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.473) / 11.532
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biomaxima  (WAR:BMX) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Biomaxima Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Biomaxima's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomaxima (WAR:BMX) Business Description

Traded in Other Exchanges
Address
5 Vetterow Street, Lublin, POL, 20-277
Biomaxima SA is a Polish company, produces microbiology media as well as a wide range of reagents and in Vitro diagnostics equipment. The company is also a distributor of products of recognized global diagnostics companies such as Nova Biomedical, Mitsubishi Chemical and Biologist. Its products include Systems Antibiotic Susceptibility Testing, Urine Analysis Systems, Hematological Reagents along with Analyzers, ion Selective Analyzers with Reagents, Immunological Analyzer of Cardiac markers with reagents, Glucose Meters and analyzers for Gasometric and Critical Blood Tests.

Biomaxima (WAR:BMX) Headlines

No Headlines